Sumitomo Pharma Co., Ltd.
SMDPY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $807,747 | $108,002,000 | $105,649,000 | $112,434,000 |
| % Growth | -99.3% | 2.2% | -6% | – |
| Cost of Goods Sold | $309,137 | $44,112,000 | $39,671,000 | $41,439,000 |
| Gross Profit | $498,610 | $63,890,000 | $65,978,000 | $70,995,000 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| R&D Expenses | $63,395 | $8,175,000 | $13,126,000 | $10,467,000 |
| G&A Expenses | $0 | $0 | $4,346,000 | $0 |
| SG&A Expenses | $277,368 | $35,657,000 | $49,565,000 | $41,044,000 |
| Sales & Mktg Exp. | $0 | $0 | $25,000,000 | $0 |
| Other Operating Expenses | $0 | -$342,000 | -$12,291,000 | -$1,921,000 |
| Operating Expenses | $340,763 | $43,490,000 | $50,400,000 | $49,590,000 |
| Operating Income | $157,847 | $20,400,000 | $15,578,000 | $21,405,000 |
| % Margin | 19.5% | 18.9% | 14.7% | 19% |
| Other Income/Exp. Net | $390,529 | -$8,468,000 | -$21,993,000 | $35,027,000 |
| Pre-Tax Income | $548,376 | $11,932,000 | -$6,415,000 | $56,432,000 |
| Tax Expense | -$46,002 | $726,000 | -$8,830,000 | $2,984,000 |
| Net Income | $594,378 | $11,206,000 | $2,415,000 | $53,448,000 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS | 1.5 | 28.21 | 6.08 | 134.53 |
| % Growth | -94.7% | 364% | -95.5% | – |
| EPS Diluted | 1.5 | 28.21 | 6.08 | 134.53 |
| Weighted Avg Shares Out | 397,290 | 397,290 | 397,290 | 397,290 |
| Weighted Avg Shares Out Dil | 397,290 | 397,290 | 397,290 | 397,290 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,435 | $0 | $0 | $35,027,000 |
| Interest Expense | $0 | $8,468,000 | $21,993,000 | $0 |
| Depreciation & Amortization | $35,790 | $5,203,000 | $5,807,000 | $6,066,000 |
| EBITDA | $584,166 | $26,241,000 | $5,604,000 | $27,471,000 |
| % Margin | 72.3% | 24.3% | 5.3% | 24.4% |